Endo International PLC (NASDAQ:ENDP) (TSE:ENL) shares gapped up before the market opened on Monday . The stock had previously closed at $4.62, but opened at $4.88. Endo International shares last traded at $4.46, with a volume of 583,518 shares traded.
ENDP has been the subject of several research analyst reports. Royal Bank of Canada restated a “hold” rating and set a $6.00 price target on shares of Endo International in a research report on Thursday, August 8th. Mizuho reiterated a “hold” rating and issued a $6.00 target price on shares of Endo International in a report on Wednesday, August 7th. Morgan Stanley set a $2.00 target price on Endo International and gave the company a “sell” rating in a report on Friday, August 9th. BidaskClub upgraded Endo International from a “strong sell” rating to a “sell” rating in a report on Friday. Finally, ValuEngine upgraded Endo International from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 2nd. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the company. Endo International presently has a consensus rating of “Hold” and an average target price of $7.89.
The stock has a market capitalization of $1.09 billion, a PE ratio of 1.61 and a beta of 1.33. The stock has a fifty day moving average of $3.43 and a 200-day moving average of $4.67.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Monday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.05. Endo International had a negative return on equity of 129.30% and a negative net margin of 19.98%. The firm had revenue of $699.71 million during the quarter, compared to analyst estimates of $694.60 million. During the same period last year, the business posted $0.76 earnings per share. Endo International’s revenue was down 2.1% compared to the same quarter last year. Equities analysts expect that Endo International PLC will post 2.17 earnings per share for the current fiscal year.
In other Endo International news, Director Roger H. Kimmel sold 25,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $4.09, for a total value of $102,250.00. Following the sale, the director now directly owns 123,309 shares in the company, valued at $504,333.81. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.50% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Arizona State Retirement System boosted its stake in shares of Endo International by 1.4% during the 2nd quarter. Arizona State Retirement System now owns 312,262 shares of the company’s stock worth $1,287,000 after acquiring an additional 4,167 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Endo International by 14.5% in the 3rd quarter. Nisa Investment Advisors LLC now owns 50,690 shares of the company’s stock valued at $163,000 after acquiring an additional 6,434 shares during the last quarter. Meeder Asset Management Inc. raised its holdings in Endo International by 47.1% in the 2nd quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock valued at $156,000 after acquiring an additional 12,127 shares during the last quarter. United Services Automobile Association raised its holdings in Endo International by 6.4% in the 2nd quarter. United Services Automobile Association now owns 218,890 shares of the company’s stock valued at $902,000 after acquiring an additional 13,126 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in Endo International by 8.9% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 196,692 shares of the company’s stock valued at $810,000 after acquiring an additional 16,125 shares during the last quarter. Institutional investors own 95.78% of the company’s stock.
Endo International Company Profile (NASDAQ:ENDP)
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Recommended Story: What is a balanced fund?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.